Dietary amelioration of Helicobacter infection

Nutrition Research

Volumn 35, Issue 6, 2014, Pages 461-473

  Fahey, Jed W ^a,b   Stephenson, Katherine K ^a   Wallace, Alison J ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c THE NEW ZEALAND INSTITUTE FOR PLANT AND FOOD RESEARCH LIMITED   (New Zealand)

Author keywords

Anti inflammatory; Cancer; Gastric; H pylori; Helicobacter; Stomach; Ulcer

Indexed keywords

CURCUMIN; ESSENTIAL OIL; PROBIOTIC AGENT; PROPOLIS; VEGETABLE OIL;

BACTERIAL CLEARANCE; BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; BERRY; BRASSICACEAE; BROCCOLI; CLINICAL EFFECTIVENESS; DAIRY PRODUCT; DIET THERAPY; DRUG EFFICACY; FOOD COMPOSITION; FRUIT; GARLIC; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HERB; HONEY; HUMAN; INFECTION CONTROL; LACTOBACILLUS; LACTOBACILLUS REUTERII; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SPICE; STOMACH CANCER; ANIMAL; EDIBLE PLANT; GROWTH, DEVELOPMENT AND AGING; HELICOBACTER INFECTIONS; MICROBIOLOGY; PHYTOTHERAPY;

ANIMALS; DAIRY PRODUCTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HONEY; HUMANS; OILS, VOLATILE; PHYTOTHERAPY; PLANTS, EDIBLE; PROBIOTICS; SPICES;

EID: 84945442923     PISSN: 02715317     EISSN: 18790739     Source Type: Journal    
DOI: 10.1016/j.nutres.2015.03.001     Document Type: Review

References (170)

1. Marshall B.J., Warren J.R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984, 1:1311-1315.
2. Whary M.T., Fox J.G. Natural and experimental Helicobacter infections. Comp Med 2004, 54:128-158.
3. Parsonnet J. Clinician-discoverers-Marshall, Warren, and H. pylori. N Engl J Med 2005, 353:2421-2423.
4. Mahady G.B. Medicinal plants for the prevention and treatment of bacterial infections. Curr Pharm Des 2005, 11:2405-2427.
5. Kusters J.G., van Vliet A.H.M., Kuipers E.J. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006, 19(3):449-490.
6. Parkin D.M., Pisani P., Ferlay J. Global cancer statistics. CA Cancer J Clin 1999, 49:33-64.
7. Holcombe C. The African enigma. Gut 1992, 33:429-431.
8. Agha A., Graham D.Y. Evidence-based examination of the African enigma in relation to Helicobacter pylori infection. Scand J Gastroenterol 2005, 40:523-529.
9. Bravo L.E., van Doom L.-J., Realpe J.L., Correa P. Virulence-associated genotypes of Helicobacter pylori: do they explain the African enigma?. Am J Gastroenterol 2002, 97:2839-2842.
10. Kodama N., Pazos A., Schneider G.B., Piazuelo M.B., Mera R., Sobota R.S., et al. Human and Helicobacter pylori coevolution shapes the risk of gastric disease. Proc Natl Acad Sci U S A 2014, 111(4):1455-1460.
11. Shiota S., Suzuki R., Yamaoka Y. The significance of virulence factors in Helicobacter pylori. J Dig Dis 2013, 14:341-349.
12. World Health Organization Global health observatory data repository. Number of deaths (World) by cause 2011, [Available from: http://apps.who.int/gho/data/node.main].
13. Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN. Int J Cancer 2012, E359-E386. [20145]. 10.1002/ijc.29210136.
14. Correa P. Helicobacter pylori infection and gastric cancer. Cancer Epidemiol Biomarkers Prev 2003, 12:238s-241s.
15. Greenberg E.R., Alberts D.S., Potter J.D. Introduction: what should we do now about H. pylori?. Cancer Epidemiol Biomarkers Prev 2005, 14:1851-1852.
16. Arora S., Czinn S.J. Vaccination as a method of preventing Helicobacter pylori associated gastric cancer. Cancer Epidemiol Biomarkers Prev 2005, 14:1890-1891.
17. Zawahir S., Czinn S.J., Nedrud J.G., Blanchard T.G. Vaccinating against Helicobacter pylori in the developing world. Gut Microbes 2013, 4(6):568-576.
18. Graham K.S., Graham D.Y. Contemporary diagnosis and management of H pylori-associated gastrointestinal diseases 2002, Handbooks in Healthcare, Newtown PA. 2nd ed.
19. Papastergiou V., Georgopoulos S.D., Karatapanis S. Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance. World J Gastroenterol 2014, 20(29):9898-9911.
20. Blaser M.J. Not all Helicobacter pylori strains are created equal: should all be eliminated?. Lancet 1997, 349:1020-1022.
21. Blaser M.J., Berg D.E. Helicobacter pylori genetic diversity and risk of human disease. J Clin Invest 2001, 107:767-773.
22. Makobongo M.O., Gilbreath J.J., Merrell D.S. Nontraditional therapies to treat Helicobacter pylori infection. J Microbiol 2014, 52(4):259-272.
23. Fukai T., Marum A., Kaitou K., Kanda T., Terada S., Nomura T. Anti-Helicobacter pylori flavonoids from licorice extract. Life Sci 2002, 71:1449-1463.
24. Manyi-Loh C.E., Clarke A.M., Mkwetshana N.F., Ndip R.N. Treatment of Helicobacter pylori infections: mitigating factors and prospective natural remedies. Afr J Biotechnol 2010, 9(14):2032-2042.
25. Cwikla C., Schmidt K., Matthias A., Bone K.M., Lehmann R., Tiralongo E. Investigations into the antibacterial activities of phytotherapeutics against Helicobacter pylori and Campylobacter jejuni. Phytother Res 2010, 24(5):649-656.
26. Bakhtaoui F.-Z., Lakmichi H., Megraud F., Chait A., Gadhi C.-E.A. Gastro-protective, anti-Helicobacter pylori and antioxidant properties of Moroccan Zizyphus lotus L. J Appl Pharm Sci 2014, 4(10):81-87.
27. Eng-Chong T., Yean-Kee L., Chin-Fei C., Choon-Han H., Sher-Ming W., Li-Ping C.T., et al. Boesenbergia rotunda: from ethnomedicine to drug discovery. Evidence-Based Compl Altern Med 2012, [Article ID 473637, 25 pp]. 10.1155/2012/473637.
28. Gadekar R., Singour P.K., Chaurasiya P.K., Pawar R.S., Patil U.K. A potential of some medicinal plants as an antiulcer agents. Pharmacogn Rev 2010, 4(8):136-146.
29. Rastall R.A., Gibson G.R. Recent developments in prebiotics to selectively impact beneficial microbes and promote intestinal health. Curr Opin Biotechnol 2015, 32:42-46.
30. Lawal T.O., Soni K.K., Doyle B.J., Adeniyi B.A., Mahady G.B. Susceptibility of Helicobacter pylori to natural products: can past research direct future drug development?. Curr Bioact Compd 2012, 8:266-276.
31. Manyi-Loh C.E., Clarke A.M., Munzhelele T., Green E., Mkwetshana N.F., Ndip R.N. Selected South African honeys and their extracts possess in vitro anti-Helicobacter pylori activity. Arch Med Res 2010, 41:324-332.
32. Fahey J.W., Kensler T.W. Health span extension through green chemoprevention. Am Med Assoc Virtual Mentor 2013, 15(4):311-318.
33. Blaser M.J. An endangered species in the stomach. Sci Am 2005, 38-45.
34. Whitfield J. The ulcer bug: gut reaction. Nature 2003, 423:583-584.
35. Chen Y., Blaser M.J. Association between gastric Helicobacter pylori colonization and glycated haemoglobin levels. J Infect Dis 2012, 205:1195-1202.
36. Holster I.L., Vila A.M.J., Caudri D., den Hoed C.M., Perez-Perez G.I., Blaser M.J., et al. The impact of Helicobacter pylori on atopic disorders in childhood. Helicobacter 2012, 17:232-237.
37. Gotteland M., Cruchet S., Brunser O. Can the amount of Helicobacter pylori in the stomach be kept low through probiotic intake?. Am J Clin Nutr 2005, 81:939.
38. Gaby A.R. Helicobacter pylori eradication: are there alternatives to antibiotics?. Altern Med Rev 2001, 6:355-366.
39. Blaser M.J. The Jeremiah Metzger lecture: global warming redux: the disappearing microbiota and epidemic obesity. Trans Am Clin Climatol Assoc 2012, 123:230-241.
40. Cho I., Blaser M.J. The human microbiome: at the interface of health and disease. Nat Rev Genet 2012, 13:260-270.
41. Cooke C.L., Torres J., Solnick J.V. Biomarkers of Helicobacter pylori-associated gastric cancer. Gut Microbes 2013, 4(6):532-540.
42. Wu M.-S., Chow L.-P., Lin J.-T., Chiou S.-H. Proteomic identification of biomarkers related to Helicobacter pylori-associated gastroduodenal disease: challenges and opportunities. J Gastroenterol Hepatol 2008, 23(11):1657-1661.
43. Graham D.Y., Osato M. Response to Drs. Mahady and Pendland-pretreatment testing for H. pylori in duodenal ulcer disease. Am J Gastroenterol 2000, 95:309-310.
44. Mahady G.B., Pendland S. Garlic and Helicobacter pylori. Am J Gastroenterol 2000, 95:309.
45. Yanaka A., Zhang S., Tauchi M., Nakahara A., Tanaka N. Daily intake of sulforaphane-rich broccoli sprouts prevents progression of high salt diet-induced gastric atrophy in Helicobacter pylori-infected C57/BL6 mice in vivo. Jpn J Helicobacter Res 2004, 5:9-13.
46. Yanaka A., Fahey J.W., Fukumoto A., Nakayama M., Inoue S., Zhang S., et al. Dietary sulforaphane-rich broccoli sprouts reduce colonization and attenuate gastritis in Helicobacter pylori-infected mice and humans. Cancer Prev Res 2009, 2(4):353-360.
47. Camargo M.C., Garcia A., Riquelme A., Otero W., Camargo C.A., Hernandez-Garcia T., et al. The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America. Am J Gastroenterol 2014, 109:485-495.
48. Fahey J.W., Talalay P., Kensler T.W. Notes from the field: "green" chemoprevention as frugal medicine. Cancer Prev Res 2012, 5(2):179-188.
49. Liu H., Dinkova-Kostova A.T., Talalay P. Coordinate regulation of enzyme markers for inflammation and for protection against oxidants and electrophiles. Proc Natl Acad Sci U S A 2008, 105(41):15926-15931.
50. Zhang Y. Molecular mechanism of rapid cellular accumulation of anticarcinogenic isothiocyanates. Carcinogenesis 2001, 22(3):425-431.
51. Carson C.F., Riley T.V. Non-antibiotic therapies for infectious diseases. Commun Dis Intell 2003, 27:S144-S147.
52. Colombo E., Sangiovanni E., Dell'Agli M. A review on the anti-inflammatory activity of pomegranate in the gastrointestinal tract. Evid Based Compl Alt Med 2013, 247145:1-11. 10.1155/2013/247145.
53. Bergonzelli G.E., Donnicola D., Porta N., Corthesy-Theulaz I.E. Essential oils as components of a diet-based approach to management of Helicobacter infection. Antimicrob Agents Chemother 2003, 47:3240-3246.
54. Ohno T., Kita M., Yamaoka Y., et al. Antimicrobial activity of essential oils against Helicobacter pylori. Helicobacter 2003, 8:207-215.
55. Holtmann G., Haag S., Adam B., Funk P., Wieland V., Heydenreich C.R. Effects of a fixed combination of peppermint oil and caraway oil on symptoms and quality of life in patients suffering from functional dyspepsia. Phytomedicine 2003, 10:56-57.
56. Martin K.W., Ernst E. Herbal medicines for treatment of bacterial infections: a review of controlled clinical trials. J Antimicrob Chemother 2003, 51:241-246.
57. Chun K.S., Kim E.H., Lee S., Hahm K.B. Chemoprevention of gastrointestinal cancer: the reality and the dream. Gut Liver 2013, 7(2):137-149.
58. [Accessed Dec 8, 2014]. http://clinicaltrials.gov/ct2/results/map/click?map.x=100&map.y=360&term=helicobacter.
59. McGovern D.P.B., Abbas S.Z., Vivian G., Dalton H.R. Manuka honey against Helicobacter pylori. J R Soc Med 1999, 92:439.
60. Zou J., Dong J., Yu X. Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Helicobacter 2009, 14:97-107.
61. Yoon H., Kim N., Kim J.Y., Park S.Y., Park J.H., Jung H.C., et al. Effects of multistrain probiotic-containing yogurt on second-line triple therapy for Helicobacter pylori infection. J Gastroenterol Hepatol 2011, 26(1):44-48.
62. Iannitti T., Palmieri B. Therapeutical use of probiotic formulations in clinical practice. Clin Nutr 2010, 29:701-725.
63. Medeiros J.A., Gonçalves T.M., Boyanova L., Pereira M.I., de Carvalho J.N., Pereira A.M., et al. Evaluation of Helicobacter pylori eradication by triple therapy plus Lactobacillus acidophilus compared to triple therapy alone. Eur J Clin Microbiol Infect Dis 2011, 30(4):555-559.
64. Lionetti E., Indrio F., Pavone L., Borrelli G., Cavallo L., Francavilla R. Role of probiotics in pediatric patients with Helicobacter pylori infection: a comprehensive review of the literature. Helicobacter 2010, 15(2):79-87.
65. Song M.J., Park D.I., Park J.H., Kim H.J., Cho Y.K., Sohn C.I., et al. The effect of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of Helicobacter pylori. Helicobacter 2010, 15(3):206-213.
66. Szajewska H., Horvath A., Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther 2010, 32:1069-1079.
67. Boonyaritichaikij S., Kuwabara K., Nagano J., Kobayashi K., Koga Y. Long-term administration of probiotics to asymptomatic pre-school children for either the eradication or the prevention of Helicobacter pylori infection. Helicobacter 2009, 14(3):202-207.
68. Sachdeva A., Rawat S., Nagpal J. Efficacy of fermented milk and whey proteins in Helicobacter pylori eradication: a review. World J Gastroenterol 2014, 20(3):724-737.
69. Sachdeva A., Nagpal J. Effect of fermented milk-based probiotic preparations on Helicobacter pylori eradication: a systematic review and meta-analysis of randomized-controlled trials. Eur J Gastroenterol Hepatol 2009, 21(1):45-53.
70. Okuda M., Nakazawa T., Yamauchi K., Miyashiro E., Koizumi R., Booka M., et al. Bovine lactoferrin is effective to suppress Helicobacter pylori colonization in the human stomach: a randomized, double-blind, placebo controlled study. J Infect Chemother 2005, 11:265-269.
71. Zullo A., De Francesco V., Scaccianoce G., Hassan C., Panarese A., Piglionica D., et al. Quadruple therapy with lactoferrin for Helicobacter pylori eradication: a randomised, multicentre study. Dig Liver Dis 2005, 37:496-500.
72. Guttner Y., Windsor H.M., Viiala C.H., Marshall B.J. Human recombinant lactoferrin is ineffective in the treatment of human Helicobacter pylori infection. Aliment Pharmacol Ther 2003, 17:125-129.
73. Bahadoran Z., Mirmiran P., Yeganeh M.Z., Hosseinpanah F., Zojaji H., Azizi F. Complementary and alternative medicinal effects of broccoli sprouts powder on Helicobacter pylori eradication rate in type 2 diabetic patients: a randomized clinical trial. J Funct Foods 2014, 7(1):390-397.
74. Galan M.V., Kishan A.A., Silverman A.L. Oral broccoli sprouts for the treatment of Helicobacter pylori infection: a preliminary report. Dig Dis Sci 2004, 48:1088-1090.
75. Opekun A.R., Yeh C.W., Opekun J.L., Graham D.Y. In vivo tests of natural therapy, Tibetan yogurt or fresh broccoli for Helicobacter pylori infection. Methods Find Exp Clin Pharmacol 2005, 27:327-329.
76. Hara M., Hanaoka T., Kobayashi M., Otani T., Yukari A., Montani A., et al. Cruciferous vegetables, mushrooms, and gastrointestinal cancer risks in a multicenter, hospital-based case-control study in Japan. Nutr Cancer 2003, 46:138-147.
77. Graham D.Y., Anderson S.-Y., Lang T. Garlic or jalapeño peppers for treatment of Helicobacter pylori infection. Am J Gastroenterol 1999, 94:1200-1202.
78. Mhaskar R.S., Ricardo I., Azliyati A., Laxminarayan R., Amol B., Santosh W., et al. Assessment of risk factors of Helicobacter pylori infection and peptic ulcer disease. J Global Infect Dis 2013, 5(2):60-67.
79. Gotteland M., Andrews M., Toledo M., Munoz L., Caceres P., Anziani A., et al. Modulation of Helicobacter pylori colonization with cranberry juice and Lactobacillus johnsonii La1 in children. Nutrition 2008, 24:421-426.
80. Zhang L., Ma J., Pan K., Go V.L., Chen J., You W.C. Efficacy of cranberry juice on Helicobacter pylori infection: a double-blind, randomized placebo-controlled trial. Helicobacter 2005, 10:139-145.
81. Frieri G., Pimpo M.T., Palombieri A., Melideo D., Marcheggiano A., Caprilli R., et al. Polyunsaturated fatty acid dietary supplementation: an adjuvant approach to treatment of Helicobacter pylori infection. Nutr Res 2000, 20:907-916.
82. Meier R., Wettstien A., Drewe J., Geiser H.R. Fish oil (Eicosapen) is less effective than metronidazole, in combination with pantoprazole and clarithromycin, for Helicobacter pylori eradication. Aliment Pharmacol Ther 2001, 15:851-855.
83. Donatini B. Randomized study comparing the efficacy of hericium versus essential oils against Helicobacter pylori (HP) infection. [Étude randomisée comparant l'efficacité d'Hericium erinaceus versus huiles essentielles sur Helicobacter pylori (HP)]. Phytothérapie 2014, 12(1):3-5.
84. Dabos K.J., Sfika E., Vlatta L.J., Giannikopoulos G. The effect of mastic gum on Helicobacter pylori: a randomized pilot study. Phytomedicine 2010, 17:296-299.
85. Bebb J.R., Bailey-Flitter N., Ala'Aldeen D., Atherton J.C. Mastic gum has no effect on Helicobacter pylori load in vivo. J Antimicrob Chemother 2003, 52:522-523.
86. Nir Y., Potasman I., Stermer E., Tabak M., Neeman I. Controlled trial of the effect of cinnamon extract on Helicobacter pylori. Helicobacter 2000, 5:94-97.
87. Keenan J.I., Salm N., Wallace A.J., Hampton M.B. Using food to reduce H. pylori-associated inflammation. Phytother Res 2012, 26(11):1620-1625.
88. Osato M.S., Reddy S.G., Graham D.Y. Osmotic effect of honey on growth and viability of Helicobacter pylori. Dig Dis Sci 1999, 44:462-464.
89. Namias N. Honey in the management of infections. Surg Infect 2003, 4:219-226.
90. Miorin P.L., Levy N.C.J., Custodio A.R., Bretz W.A., Marcucci M.C. Antibacterial activity of honey and propolis from Apis mellifera and Tetragonisca angustula against Staphylococcus aureus. J Appl Microbiol 2003, 95:913-920.
91. Cooper R.A., Molan P.C., Harding K.G. Antibacterial activity of honey against strains of Staphylococcus aureus from infected wounds. J R Soc Med 1999, 92:283-285.
92. Molan P. Honey: antimicrobial actions and role in disease management. New Strategies Combating Bacterial Infection 2009, 229-253. Wiley VCH, Weinheim. I. Ahmad, F. Aqil (Eds.).
93. Keenan J.I., Salm N., Hampton M.B., Wallace A.J. Individual and combined effects of foods on Helicobacter pylori growth. Phytother Res 2010, 24(8):1229-1233.
94. Al Somal N., Coley K.E., Molan P.C., Hancock B.M. Susceptibility of Helicobacter pylori to the antibacterial activity of manuka honey. J R Soc Med 1994, 87:9-12.
95. Banskota A.H., Tezuka Y., Adnyana I.K., et al. Hepatoprotective and anti-Helicobacter pylori activities of constituents from Brazilian propolis. Phytomedicine 2001, 8:16-23.
96. Boyanova L., Derejian S., Koumanova R., et al. Inhibition of Helicobacter pylori growth in vitro by Bulgarian propolis: preliminary report. J Med Microbiol 2003, 52:417-419.
97. Gill H.S. Probiotics to enhance anti-infective defences in the gastrointestinal tract. Best Pract Res Clin Gastroenterol 2003, 17:755-773.
98. Pagliaro G., Battino M. The use of probiotics in gastrointestinal diseases. Mediterr J Nutr Metab 2010, 3:105-113.
99. Felley C., Michetti P. Probiotics and Helicobacter pylori. Best Pract Res Clin Gastroenterol 2003, 17:785-791.
100. Johnson-Henry K.C., Mitchell D.J., Avitzur Y., Galindo-Mata E., Jones N.L., Sherman P.M. Probiotics reduce bacterial colonization and gastric inflammation in H. pylori-infected mice. Dig Dis Sci 2004, 49:1095-1102.
101. Dang Y., Reinhardt J.D., Zhou X., Zhang G. The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: a meta-analysis. PLoS ONE 2014, 9(11):e111030. 10.1371/journal.pone.0111030.
102. Sgouras D., Maragkoudakis P., Petraki K., Martinez-Gonzalez B., Eriotou E., Michopoulos S., et al. In vitro and in vivo inhibition of Helicobacter pylori by Lactobacillus casei strain Shirota. Appl Environ Microbiol 2004, 71:518-526.
103. Hamilton-Miller J.M.T. The role of probiotics in the treatment and prevention of Helicobacter pylori infection. Int J Antimicrob Agents 2003, 22:360-366.
104. Dial E.J., Hall L.R., Serna H., Romero J.J., Fox J.G., Lictenbergerger L.M. Antibiotic properties of bovine lactoferrin on Helicobacter pylori. J Clin Microbiol 1998, 34:2593-2594.
105. Husson M.O., Legrand D., Spik G., Leclerc H. Iron acquisition by Helicobacter pylori: importance of human lactoferrin. Infect Immunol 1993, 61:2694-2697.
106. Miehkle S., Reddy R., Osato M.S., Ward P.P., Conneely O.M., Graham D.Y. Direct activity of recombinant human lactoferrin against Helicobacter pylori. J Clin Microbiol 1996, 34:2593-2594.
107. Dial E.J., Lictenbergerger L.M. Effect of lactoferrin on Helicobacter felis induced gastritis. Biochem Cell Biol 2002, 80:113-117.
108. Dial E.J., Romero J.J., Headon D.R., Lictenbergerger L.M. Recombinant human lactoferrin is effective in the treatment of Helicobacter felis-infected mice. J Pharm Pharmacol 2000, 52:1541-1546.
109. Akedo I., Tatsuta M., Narahara H., Iishi H., Uedo N., Yano H., et al. Prevention by bovine milk against Helicobacter pylori-associated atrophic gastritis through its adherence inhibition. Hepato-Gastroenterology 2004, 51:277-281.
110. Jantscher-Krenn E., Bode L. Human milk oligosaccharides and their potential benefits for the breast-fed neonate. Minerva Pediatr 2012, 64(1):83-99.
111. Yanaka A. Sulforaphane enhances protection and repair of gastric mucosa against oxidative stress via nrf2-dependent mechanisms. Front Gastrointest Res 2012, 30:170-180.
112. Yanaka A., Zhang S., Tauchi M., Suzuki H., Shibahara T., Matsui H., et al. Role of nrf-2 gene in protection and repair of gastric mucosa against oxidative stress. Inflammopharmacology 2005, 13:83-90.
113. Yamada T., Wei M., Toyoda T., Yamano S., Wanibuchi H. Inhibitory effect of Raphanobrassica on Helicobacter pylori-induced gastritis in Mongolian gerbils. Food Chem Toxicol 2014, 70:107-113.
114. Yanaka A., Tauchi M., Yamamoto M. Effects of sulforaphane-rich broccoli sprouts on H. pylori-infected gastric mucosa. Nippon Rinsho 2005, 63:582-586.
115. Yanaka A., Zhang S., Yamamoto M., Fahey J.W. Daily intake of sulforaphane-rich broccoli sprouts improves gastritis in H. pylori infected human subjects. Cancer Epidemiol Biomarkers Prev 2005, 14:2754s.
116. Fahey J.W., Haristoy X., Dolan P.M., Kensler T.W., Scholtus I., Stephenson K.K., et al. Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. Proc Natl Acad Sci U S A 2002, 99:7610-7615.
117. Haristoy X., Fahey J.W., Scholtus I., Lozniewski A. Evaluation of the antimicrobial effects of several isothiocyanates on Helicobacter pylori. Planta Med 2005, 71:326-330.
118. Haristoy X., Angioi-Duprez K., Duprez A., Lozniewski A. Efficacy of sulforaphane in eradicating Helicobacter pylori in human gastric xenografts implanted in nude mice. Antimicrob Agents Chemother 2003, 47:3982-3984.
119. Canizares P., Gracia I., Gomez L.A., de Argila C.M., de Rafael L., Garcia A. Optimization of Allium sativum solvent extraction for the inhibition of in vitro growth of Helicobacter pylori. Biotechnol Prog 2002, 18:1227-1232.
120. Burger O., Weiss E., Sharon N., Tabak M., Neeman I., Ofek I. Inhibition of Helicobacter pylori adhesion to human gastric mucus by a high-molecular weight constituent of cranberry juice. Crit Rev Food Sci Nutr 2002, 42:279-284.
121. Sharon N., Ofek I. Fighting infectious disease with inhibitors of microbial adhesion to host tissues. Crit Rev Food Sci Nutr 2002, 42:267-272.
122. Shmuely H., Burger O., Neeman I., Yahav J., Samra Z., Niv Y., et al. Susceptibility of Helicobacter pylori isolates to the antiadhesion activity of a high-molecular-weight constituent of cranberry. Diagn Microbiol Infect Dis 2004, 50:231-235.
123. Chatterjee A., Yasmin T., Bagchi D., Stohs S.J. Inhibition of Helicobacter pylori in vitro by various berry extracts, with enhanced susceptibility to clarithromycin. Mol Cell Biochem 2004, 265:19-26.
124. Pastene E., Speisky H., Garcia A., Moreno J., Troncoso M., Figueroa G. In vitro and in vivo effects of apple peel polyphenols against Helicobacter pylori. J Agric Food Chem 2010, 58:7172-7179.
125. Friedman M. Antibacterial, antiviral, and antifungal properties of wines and winery byproducts in relation to their flavonoid content. J Agric Food Chem 2014, 62(26):6025-6042.
126. Ghaedi M., Darvishi S., Rezaee M.A., Motaharinia Y., Ghavami K., Rahmani M.R. Antibacterial activity of extracts of halgho and rashe grape cultivars against Helicobacter pylori. J Pure Appl Microbiol 2013, 7(3):1895-1901.
127. Drago L., Mombelli B., Ciardo G., De Vecchi E., Gismondo M.R. Effects of three different fish oil formulations on Helicobacter pylori growth and viability: in vitro study. J Chemother 1999, 11:207-210.
128. Ozen F., Ekinci F.Y., Korachi M. The inhibition of Helicobacter pylori infected cells by Origanum minutiflorum. Ind Crop Prod 2014, 58:329-334.
129. Park C.-G., Lee A.Y., Lee J.H., Lee J.M., Park J.Y., Lee S.-H., et al. Biological activities of licorice f1 lines and content analysis of phytochemical constituents. Nat Prod Sci 2014, 20(3):137-145.
130. Park J.-M., Park S.-H., Hong K.-S., Han Y.-M., Jang S.-H., Kim E.-H., et al. Special licorice extracts containing lowered glycyrrhizin and enhanced licochalcone A prevented Helicobacter pylori-initiated, salt diet-promoted gastric tumorigenesis. Helicobacter 2014, 19(3):221-236.
131. Bhamarapravati S., Pendland S.L., Mahady G.B. Extracts of spice and food plants from Thai traditional medicine inhibit the growth of the human carcinogen Helicobacter pylori. In Vivo 2003, 17:541-544.
132. Huwez F.U., Thirlwell D., Cockayne A., Ala'Aldeen D.A. Mastic gums kills Helicobacter pylori. N Engl J Med 1998, 339:1946.
133. Wittschier N., Faller G., Hensel A. Aqueous extracts and polysaccharides from liquorice roots (Glycyrrhiza glabra L.) inhibit adhesion of Helicobacter pylori to human gastric mucosa. J Ethnopharmacol 2009, 125:218-223.
134. Shibata H., Iimuro M., Uchiya N., Tshihiko K., Nagaoka M., Ueyama S., et al. Preventive effects of Cladosiphon fucoidan against Helicobacter pylori infection in Mongolian gerbils. Helicobacter 2003, 8:59-65.
135. Matsubara S., Shibata H., Ishikawa F., Yokokura T., Takahashi M., Sugimura T., et al. Suppression of Helicobacter pylori-induced gastritis by green tea extract in Mongolian gerbils. Biochem Biophys Res Commun 2003, 310:715-719.
136. Li Y., Xu C., Zhang Q., Kiu J.Y., Tan R.X. In vitro anti-Helicobacter pylori action of 30 Chinese herbal medicines used to treat ulcer diseases. J Ethnopharmacol 2005, 98:329-333.
137. Ma F., Chen Y., Li J., Qing H.-P., Wang J.-D., Zhang Y.-L., et al. Screening test for anti-Helicobacter pylori activity of traditional Chinese herbal medicines. World J Gastroenterol 2010, 16(44):5629-5634.
138. Haniandka R., Saldanha E., Sunita V., Palatty P.L., Rayad R., Baliga M.S. A review of the gastroprotective effects of ginger (Zingiber officinale Roscoe). Food Funct 2013, 4:845-855.
139. Lutay N., Nilsson I., Wadström T., Ljungh Å. Effect of heparin, fucoidan and other polysaccharides on adhesion of enterohepatic Helicobacter species to murine macrophages. Appl Biochem Biotechnol 2011, 164(1):1-9.
140. Molan P.C. Re-introducing honey in the management of wounds and ulcers-theory and practice. Ostomy Wound Manage 2002, 48:28-40.
141. Hill C., Guarner F., Reid G., Gibson G.R., Merenstein D.J., Pot B., et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014, 11(8):506-514.
142. Malfertheiner P., Megraud F., O'Morain C.A., Atherton J., Axon A.T.R., Bazzoli F., et al. Management of Helicobacter pylori infection-the Maastricht IV Florence consensus report. Gut 2012, 61:646-664.
143. Fahey J.W., Stephenson K.K., Wade K.L., Talalay P. Urease from Helicobacter pylori is inactivated by sulforaphane and other isothiocyanates. Biochem Biophys Res Commun 2013, 435:1-7.
144. Fahey J.W., Muñoz A., Matsuzaki Y., Suzuki H., Talalay P., Tauchi M., et al. Dietary amelioration of Helicobacter pylori infection: design criteria for a clinical trial. Cancer Epidemiol Biomarkers Prev 2004, 13:1610-1616.
145. Herr I., Büchler M.W. Dietary constituents of broccoli and other cruciferous vegetables: implications for prevention and therapy of cancer. Cancer Treat Rev 2010, 36(5):377-383.
146. Øverby A., Zhao C.-M., Chen D. Plant phytochemicals: potential anticancer agents against gastric cancer. Curr Opin Pharmacol 2014, 19:6-10.
147. Fahey J.W. Brassicas. Encyclopedia of food science and nutrition 2003, 606-613. Academic Press, London. B. Caballero, L.L. Trujo, P.M. Finglas (Eds.).
148. Fahey J.W. Moringa oleifera: a review of the medical evidence for its nutritional, therapeutic, and prophylactic properties. Part 1. Trees Life J 2005, 1:5. [http://www.tfljournal.org/article.php/20051201124931586].
149. Lengsfeld C., Titgemeyer F., Faller G., Hensel A. Glycosylated compounds from okra inhibit adhesion of Helicobacter pylori to human gastric mucosa. J Agric Food Chem 2004, 52:1495-1503.
150. Krauze-Baranowska M., Majdan M., Hałasa R., Głód D., Kula M., Fecka I., et al. The antimicrobial activity of fruits from some cultivar varieties of Rubus idaeus and Rubus occidentalis. Food Funct 2014, 5(10):2536-2541.
151. Bhandari P.R. Garlic (Allium sativum L.): a review of potential therapeutic applications. Int J Green Pharm 2012, 6(2):118-129.
152. Serafini M., Bellocco R., Wolk A., Ekstrom A.M. Total antioxidant potential of fruit and vegetables and risk of gastric cancer. Gastroenterology 2002, 123:985-991.
153. al-Shabanah O.A. Effect of evening primrose oil on gastric ulceration and secretion induced by various ulcerogenic and necrotizing agents in rats. Food Chem Toxicol 1997, 35:769-775.
154. Duggan A.E., Atherton J.C., Cockayne A. Clarification of the link between polyunsaturated fatty acids and Helicobacter pylori-associated duodenal ulcer disease: a dietary intervention study. Br J Nutr 1997, 78:515-522.
155. Thompson L., Cockayne A., Spiller R.C. Inhibitory effect of polyunsaturated fatty acids on the growth of Helicobacter pylori: a possible explanation of the effect of diet on peptic ulceration. Gut 1994, 35:1557-1561.
156. Khulusi S., Ahmed H.A., Patel P., Mendall M.A., Northfield T.C. The effects of unsaturated fatty acids on Helicobacter pylori in vitro. J Med Microbiol 1995, 42:276-282.
157. Aldoori W.H., Giovannucci E.L., Stampfer M.J., Rimm E.B., Wing A.L., Willett W.C. Prospective study of diet and the risk of duodenal ulcer in men. Am J Epidemiol 1997, 145:42-50.
158. Calder P.C. N-3 polyunsaturated fatty acids and inflammation: from molecular biology to the clinic. Lipids 2003, 38:343-352.
159. Jayaraj A.P., Tovey F.I., Lewin M.R., Clark C.G. Duodenal ulcer prevalence: experimental evidence for the possible role of dietary lipids. J Gastroenterol Hepatol 2000, 15:610-616.
160. Ito Y., Suzuki K., Ichino N., et al. The risk of Helicobacter pylori infection and atrophic gastritis from food and drink intake: a cross-sectional study in Hokkaido, Japan. Asian Pac J Cancer Prev 2000, 1:147-156.
161. Das U.N. Hypothesis: cis-unsaturated fatty acids as potential anti-peptic ulcer drugs. Prostaglandins Leukot Essent Fatty Acids 1998, 58:377-380.
162. Petschow B.W., Batema R.P., Ford L.L. Susceptibility of Helicobacter pylori to bactericidal properties of medium-chain monoglycerides and free fatty acids. Antimicrob Agents Chemother 1996, 40:302-306.
163. Petschow B.W. Use of lauric acid or a monoglyceride of a C8-C16 fatty acid for inhibiting Helicobacter 1996, Squibb Bristol-Myers Co, Europe, [esp at cenet].
164. Mysore J.V., Wigginton T., Simon P.M., Zopf D., Heman-Achah L.M., Dubois A. Treatment of Helicobacter pylori infection in rhesus monkeys using a novel antiadhesion compound. Gastroenterology 1999, 117(6):1316-1325.
165. Tabak M., Armon R., Rosenblat G., Stermer E., Neeman I. Diverse effects of ascorbic acid and palmitoyl ascorbate on Helicobacter pylori survival and growth. FEMS Microbiol Lett 2003, 224:247-253.
166. Phull P.S., Green C.J., Jacyna M.R. A radical view of the stomach: the role of oxygen-derived free-radicals and anti-oxidants in gastroduodenal disease. Eur J Gastroenterol Hepatol 1995, 7:265-274.
167. Lacy B.E., Rosemore J. Helicobacter pylori: ulcers and more: the beginning of an era. J Nutr 2001, 131:2789S-2793S.
168. Yoshida T., Hatano T., Ito H. Chemistry and function of vegetable polyphenols with high molecular weights. Biofactors 2000, 13:121-125.
169. Beil W., Birkholz C., Sewing K.F. Effects of flavonoids on parietal cell acid secretion, gastric mucosal prostaglandin production and Helicobacter pylori growth. Arzneimittelforschung 1995, 45:697-700.
170. Bae E.-A., Han M.J., Kim D.-H. In vitro anti-Helicobacter pylori activity of some flavonoids and their metabolites. Planta Med 1999, 6:442-443.